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Abstract Prosthetic joint infections (PJIs) are rare but long-
lasting and are serious complications without any spontaneous
resolution, requiring additional surgery and long-term treat-
ment with antibiotics. Staphylococci are the most important
aetiological agents of PJIs, and among the coagulase-negative
staphylococci Staphylococcus epidermidis is the most com-
mon. However, S. epidermidis often displays multidrug resis-
tance (MDR), demanding additional treatment options. The
objective was to examine the effectiveness of tedizolid and
linezolid against S. epidermidis isolated from PJIs. The stan-
dard antibiotic susceptibility pattern of S. epidermidis (n =
183) obtained from PJIs was determined by disc diffusion test,
and MIC was determined by Etest for tedizolid, linezolid, and
vancomycin. Tedizolid displayed MIC values ranging from
0.094 to 0.5 mg/L (MIC50: 0.19 mg/L, MIC90: 0.38 mg/L),
linezolid MIC values ranging from 0.25 to 2 mg/L (MIC50:
0.75 mg/L, MIC90: 1 mg/L), and vancomycin MIC values
ranging from 0.5 to 3 mg/L (MIC50 and MIC90 both 2 mg/
L). According to the disc diffusion test, 153/183 (84%) isolates
were resistant to ≥3 antibiotic groups, indicating MDR. In
conclusion, S. epidermidis isolates from PJIs were fully sus-
ceptible, and the MIC50 and MIC90 values for tedizolid were
two- to four-fold dilution steps lower compared with linezolid.
Tedizolid is not approved, and there are no reports of long-term
treatment, but it may display better tolerability and fewer ad-
verse effects than linezolid; it thus could be a possible treat-
ment option for PJIs, alone or in combination with rifampicin.
Introduction
Joint replacements have significantly improved the quality of
life for many patients. Prosthetic joint infections (PJIs) are rare
complications, affecting less than 1% of primary joint replace-
ment surgeries [1]. However, PJIs are long-lasting and serious
conditions without any spontaneous resolution, causing high
morbidity and mortality, extensive costs, and substantial suf-
fering for the patient due to disability, pain, prolonged hospi-
talization, revision surgery, and long-term treatment with an-
tibiotics [2–4].
Staphylococci are the most important aetiological agents of
PJIs [2–4], and S. epidermidis is the most common of the
CoNS. This species regularly forms a biofilm, and so the
proposed treatment of choice for PJIs is rifampicin, which is
efficient against staphylococci in biofilm [2, 4]. Rifampicin is
always administered in combination with another antimicro-
bial agent such as fluoroquinolones, clindamycin, or fusidic
acid in order to hinder the emergence of resistance [2–4].
However, S. epidermidis often displays a multidrug resistance
(MDR) phenotype [5]. Linezolid could be one of the few
remaining options for oral long-term treatment, but is bacteri-
ostatic, not proven to eradicate staphylococci present in bio-
film [6], and frequently exhibits adverse effects [7].
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Nevertheless, it has been reported to successfully treat chronic
osteomyelitis including PJIs [7, 8].
The aim of this study was to investigate the antibiotic activity
of a new oxazolidinone, tedizolid, and to compare itsMIC values
with those of linezolid, among S. epidermidis isolated from PJIs.
Materials and methods
S. epidermidis isolates (n = 183) were obtained during various
surgical procedures due to suspected or verified PJI at the
University Hospitals of Örebro and Linköping from 1999 to
2015 and from 1993 to 2015, respectively. The finding of
S. epidermidis in multiple tissue samples (≥2) was interpreted
as a PJI in accordance with the proposed definition of PJI
[3, 4]. Isolates were collected from patients with infected hip
(n = 126), knee (n = 41), shoulder (n = 12), or elbow (n = 4)
joint prostheses, then identified to the species level according
to routine laboratory procedures and confirmed by MALDI-
TOF MS (MicroflexLT and Biotyper 3.1, Bruker Daltonics,
Bremen, Germany).
Standard antibiotic susceptibility testing by disc diffusion
test (DDT) and MIC determination was performed according
to EUCAST guidelines. MIC was determined by Etest for
tedizolid, linezolid (Liofilchem, Roseto degli Abruzzi, Italy),
and vancomycin (BioMérieux, Marcy-l’Etoile, France). DDT
was performed for cefoxitin (30 μg), fusidic acid (10 μg),
erythromycin (15 μg), clindamycin (2 μg), trimethoprim/
sulfamethoxazole (25 μg), gentamicin (10 μg), norfloxacin
(10 μg), and rifampin (5 μg) (Oxoid, Basingstoke,
Hampshire, England).
Results
Results of the antimicrobial susceptibility testing of tedizolid
and linezolid are shown in Fig. 1. Tedizolid displayed MIC
values ranging from 0.094 to 0.5 mg/L (MIC50: 0.19 mg/L,
MIC90: 0.38 mg/L) and linezolid MIC values ranging from
0.25 to 2 mg/L (MIC50: 0.75 mg/L, MIC90: 1 mg/L). All
isolates were susceptible according to EUCAST breakpoints
(≤0.5 mg/L and ≤4 mg/L, respectively). The MIC values of
vancomycin ranged from 0.5 to 3 mg/L (MIC50 and MIC90
both 2 mg/L). The breakpoint for susceptibility according to
EUCAST is ≤4 mg/L.
According to the DDT, 22% of the S. epidermidis
isolates were susceptible to cefoxitin, 56% to fusidic
acid, 42% to clindamycin, 37% to erythromycin, 72%
to rifampicin, 28% to gentamicin, 19% to norfloxacin,
and 27% to sulfamethoxazole-trimethoprim. In total,
153/183 (84%) isolates were resistant to ≥3 antibiotic
groups, indicating MDR. There were no differences be-
tween isolates displaying MDR and non-MDR in MIC50
and MIC90, respectively, neither for tedizolid nor for
linezolid.
Discussion
This study investigated the antibiotic activity of a new
oxazolidinone, tedizolid, compared to linezolid against
S. epidermidis isolated from PJIs. All isolates were fully sus-
ceptible to both antibiotics according to EUCAST
breakpoints. The MIC50 and MIC90 values for tedizolid were
two- to four-fold dilution steps lower than the corresponding
values for linezolid. Our results are in concordance with pre-
vious studies [9–14].
All S. epidermidis isolates were also susceptible to vanco-
mycin according to the EUCAST breakpoint. However, 111/
183 (61%) showed MIC values ≥2 mg/L, and thus an in-
creased risk of nephrotoxicity may be present if the trough
value of the plasma concentration is intended to be approxi-
mately 20 mg/L. Heterogeneous glycopeptide intermediate
S. epidermidis (hGISE) may also be present among
S. epidermidis isolated from PJIs [15], which will not be de-
tected if only standard Etest methods are used. The present
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study also found a high percentage (84%) of MDR. The pro-
portions of isolates susceptible to the key antimicrobial agents
for oral long-term treatment of PJIs, rifampicin and
fluoroquinolones, were 72% and 19%, respectively. In addi-
tion, an association between hGISE and MDR has been re-
ported [15]. Subsequently, in some cases an oxazolidinone
may be the only remaining antimicrobial agent for oral treat-
ment of a stable, retained implant following debridement or
after explantation when performing two-stage exchange revi-
sion surgery. Linezolid has been employed for treatment of
these infections, including long-term therapy [7, 8]. Tedizolid,
on the other hand, is approved for 6 days’ treatment of skin
and soft tissue infections and there are no reports of long-term
treatment or treatment of orthopaedic infections. In a phase I
study [16], 30 healthy subjects received 200–1200 mg
tedizolid once a day for 21 days, and three showed adverse
events such as alteration of haematological parameters and
elevation of liver enzymes. Tedizolid seems to be well-toler-
ated, and adverse events are less common among patients
treated with tedizolid compared to linezolid [17]. The myelo-
suppressive effect of tedizolid seems to be lower than that of
linezolid. Neither peripheral nor optic neuropathy were found
in either patients following 10 days of treatment or rats after
up to 9 months’ exposure to high doses of tedizolid [17].
Although tedizolid is a more potent inhibitor of mitochondrial
protein synthesis than linezolid, mitochondrial recovery may
be superior for tedizolid according to dosing intervals [18].
A lower dose of tedizolid, 200 mg once daily versus
600 mg twice daily of linezolid, may also contribute to a lower
frequency or severity of reported side effects, especially if
they are serum concentration dependent [19, 20]. Despite the
two- to four-fold lowerMIC50 andMIC90 for tedizolid, the use
of the lower dose of tedizolid, a sixth of the daily dose of
linezolid, needs to be evaluated for severe infections and es-
pecially during long-term treatment. A study evaluating the
pharmacokinetics and response to exposure to tedizolid [19]
showed that the incidence of treatment-emergent side effects
increased with increased exposure to the drug. However, no
such relationship was evident regarding hematologic side ef-
fects and exposure to tedizolid in that study. On the contrary, a
recently published study [20] found alterations in haematolog-
ical parameters, especially a decrease in mean platelet count,
in a dose-dependent manner during 21-day courses of
tedizolid.
The safety, tolerability, and adverse effects of long-term
tedizolid treatment remain to be evaluated. However, tedizolid
may represent an oxazolidinone that is better accepted by pa-
tients for long-term treatment, due to its favourable adverse
effect profile and its once-a-day administration regime. Alone
or in combination with rifampicin, tedizolid could be a possi-
ble treatment option in the management of PJIs caused by
MDR S. epidermidis in both prosthesis retention following
debridement and two-stage exchange surgery.
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